Concepedia

Jill Hallin

JH

Statistics

Publications

25

Citations

5.5K

H-Index

22

Active since

2008

Affiliations

Mirati Therapeutics (United States)(Current)

Pfizer (United States)

Dana-Farber Cancer Institute

Array BioPharma (United States)

Memorial Sloan Kettering Cancer Center

Jill Hallin is an author at Mirati Therapeutics (United States) specializing in oncology, molecular oncology, and medicine.

Publications per year

2008–2025

25

Publications

25

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin, Lars D. Engstrom, Lauren Hargis et al. · Cancer Discovery · 2019 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS <sup>G12D</sup> Inhibitor

Xiaolun Wang, Shelley Allen, James F. Blake et al. · Journal of Medicinal Chemistry · 2021 · 708 citations · Full text

Medicine, Medicinal Chemistry, Oncology +14

Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of Cancer

Jay B. Fell, John P. Fischer, Brian R. Baer et al. · Journal of Medicinal Chemistry · 2020 · 594 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Jill Hallin, Vickie Bowcut, Andrew Calinisan et al. · Nature Medicine · 2022 · 507 citations

Medicine, Medicinal Chemistry, Oncology +9

Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer

Samantha B. Kemp, Noah Cheng, Nune Markosyan et al. · Cancer Discovery · 2022 · 354 citations · Full text

Medicine, Immunology, Oncology +16

1–5 of 25